Ovid Therapeutics Inc.OVID決算レポート
Nasdaq · ヘルスケア · 医薬製剤
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| Jeremy M. Levin | 9.40% | 6.9M | — | 2024-02-14 |
| Rubric Capital Management LP | 7.52% | 5.3M | — | 2024-02-12 |
| BlackRock, Inc. | 6.10% | 4.3M | — | 2024-01-29 |
| NOS. OF ABOVE PERSONS | 5.20% | 3.6M | ▲ +0.10pp | 2024-02-14 |
| Biotechnology Value Fund, L.P. | 2.80% | 2.0M | — | 2024-11-14 |
| EcoR1 Capital, LLC | 0.00% | 690.5M | — | 2024-11-14 |
インサイダー取引
Net 90d: +$0 · buys $0 / sells $0期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-04-07 | Bart Friedman | Director | Grant | 8.8K | $2.56 | $22.5K |
| 2026-04-07 | Fitzgerald Kevin Joseph | Director | Grant | 17.6K | $2.56 | $45.0K |
| 2026-04-07 | PAPADOPOULOS STELIOS | Director | Grant | 17.6K | $2.56 | $45.0K |
| 2026-03-23 | LEVIN JEREMY M | Executive Chairman | Option exercise | 47.3K | $1.40 | $66.3K |
| 2026-02-26 | Rona Jeffrey A | CBFO | Grant | 68.1K | $0.00 | $0 |
1–5 of 5